Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer
JA Meyerhardt, JW Clark, JG Supko, JP Eder… - Cancer chemotherapy …, 2007 - Springer
Purpose To determine the maximum tolerated doses (MTD), toxicities, efficacy, and
pharmacokinetics (PK) of gefitinib combined with irinotecan, 5-fluorouracil (5-FU) and …
pharmacokinetics (PK) of gefitinib combined with irinotecan, 5-fluorouracil (5-FU) and …
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.
J Meyerhardt, J Clark, J Supko, J Eder… - Cancer …, 2007 - search.ebscohost.com
To determine the maximum tolerated doses (MTD), toxicities, efficacy, and pharmacokinetics
(PK) of gefitinib combined with irinotecan, 5-fluorouracil (5-FU) and leucovorin (IFL) in …
(PK) of gefitinib combined with irinotecan, 5-fluorouracil (5-FU) and leucovorin (IFL) in …
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer
JA Meyerhardt, JW Clark, JG Supko… - Cancer …, 2007 - search.proquest.com
280_2006_411_Article-web 1..10 Page 1 Cancer Chemother Pharmacol (2007) 60:661–670
DOI 10.1007/s00280-006-0411-6 123 ORIGINAL ARTICLE Phase I study of geWtinib, irinotecan …
DOI 10.1007/s00280-006-0411-6 123 ORIGINAL ARTICLE Phase I study of geWtinib, irinotecan …
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer
JA Meyerhardt, JW Clark, JG Supko… - Cancer …, 2007 - pubmed.ncbi.nlm.nih.gov
Purpose To determine the maximum tolerated doses (MTD), toxicities, efficacy, and
pharmacokinetics (PK) of gefitinib combined with irinotecan, 5-fluorouracil (5-FU) and …
pharmacokinetics (PK) of gefitinib combined with irinotecan, 5-fluorouracil (5-FU) and …
[引用][C] Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer
JA MEYERHARDT, JW CLARK… - Cancer …, 2007 - pascal-francis.inist.fr
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic
colorectal cancer CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic …
colorectal cancer CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic …
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.
JA Meyerhardt, JW Clark, JG Supko… - Cancer …, 2007 - europepmc.org
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic
colorectal cancer. - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe …
colorectal cancer. - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe …
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer
JA Meyerhardt, JW Clark, JG Supko, JP Eder… - Cancer Chemotherapy …, 2007 - infona.pl
Purpose To determine the maximum tolerated doses (MTD), toxicities, efficacy, and
pharmacokinetics (PK) of gefitinib combined with irinotecan, 5-fluorouracil (5-FU) and …
pharmacokinetics (PK) of gefitinib combined with irinotecan, 5-fluorouracil (5-FU) and …
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer
JA Meyerhardt, JW Clark, JG Supko, JP Eder… - Cancer Chemotherapy …, 2007 - infona.pl
Purpose To determine the maximum tolerated doses (MTD), toxicities, efficacy, and
pharmacokinetics (PK) of gefitinib combined with irinotecan, 5-fluorouracil (5-FU) and …
pharmacokinetics (PK) of gefitinib combined with irinotecan, 5-fluorouracil (5-FU) and …